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HIV-speciﬁc T cellsAlthough a live attenuated HIV vaccine is not currently considered for safety reasons, a strategy inducing both
T cells and neutralizing antibodies to native assembled HIV-1 particles expressed by a replicating virus might
mimic the advantageous characteristics of live attenuated vaccine. To this aim, we generated a live attenuated
recombinant measles vaccine expressing HIV-1 Gag virus-like particles (VLPs) covered with gp160ΔV1V2
Env protein. The measles–HIV virus replicated efﬁciently in cell culture and induced the intense budding of
HIV particles covered with Env. In mice sensitive to MV infection, this recombinant vaccine stimulated high
levels of cellular and humoral immunity to both MV and HIV with neutralizing activity. The measles–HIV
virus infected human professional antigen-presenting cells, such as dendritic cells and B cells, and induced
efﬁcient presentation of HIV-1 epitopes and subsequent activation of human HIV-1 Gag-speciﬁc T cell clones.
This candidate vaccine will be next tested in non-human primates. As a pediatric vaccine, it might protect
children and adolescents simultaneously from measles and HIV.
© 2009 Elsevier Inc. All rights reserved.Introduction
Despite 25 years of intensive research, the HIV/AIDS pandemic is
still expanding over the world, and prevention efforts appear unable
to slow the spread of HIV, particularly in Sub-Saharan Africa. The best
hope for controlling this devastating disease is the development of an
effective preventive vaccine affordable to the most exposed popula-
tions living in developing countries. There are currently more than 30
ongoing clinical trials with preventive HIV vaccine candidates. Despite
a number of promising Phases I and II studies, the most advanced
candidates have been unsuccessful, so far. The halting of Merck's
adenovirus serotype 5 (Ad5)-based HIV vaccine Phase IIb trial was a
disappointment (Sekaly, 2008). The vaccine induced HIV-speciﬁc T
cell responses that were not effective at preventing HIV infection or in
reducing virus levels in infected individuals. This result challenges the
«T cell based vaccine» strategy, at least using a single non-replicating
Ad5 vector. Earlier, the monomeric recombinant gp120-based vaccine
AIDSVax, designed to induce neutralizing antibodies, proved to
neither elicit detectable antibody titers nor affect viral load in a
Phase III trial (Flynn et al., 2005). However, human monoclonal
antibodies have been described to effectively and broadly neutralizell rights reserved.primary isolates (Mascola et al., 1997), protect macaques from
infection (Baba et al., 2000; Mascola et al., 2000) and induce a
relative control of viremia in patients (Trkola et al., 2005), thus
demonstrating that antibodies contribute to HIV control. Moreover,
although a live attenuated HIV vaccine is not currently under
consideration for safety reasons, attenuated simian immunodeﬁ-
ciency virus (SIV) is able to protect macaques effectively (Daniel et al.,
1992). It appears thus that a strategy inducing both T cells and
neutralizing antibodies against native assembled HIV particles
expressed in the context of a replicating virus should mimic the
characteristics of live attenuated SIV without the risk of reversion
observed with live persisting lentiviruses.
Because the rate of HIV infection in adolescents remains high in
Africa, adolescents are key targets of prevention efforts, including
vaccination (McClure et al., 2004). A pediatric HIV vaccine to
immunize children and adolescents in poor countries should induce
long-lasting responses after a few administrations, be produced at
low cost and scaled up to millions of doses. Live attenuated vaccines
are particularly appropriate for mass vaccination in these countries as
they are inexpensive to manufacture and induce a strong immunity
and long-term memory after a single injection. To evaluate such a
pediatric vaccine approach, we previously developed a vector derived
from the live attenuated Schwarz strain of measles virus (MV)
(Combredet et al., 2003). MV vaccine is a live attenuated negatively-
stranded RNA virus proven to be one of the safest and most effective
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distributed at low cost through the Extended Program on Immuniza-
tion (EPI) of WHO, this vaccine induces life-long immunity to
measles after one or two injections. We previously showed that MV
vector stably expressed different HIV proteins and induced strong
and long-term speciﬁc neutralizing antibodies and cellular immune
responses to HIV, even in presence of preexisting immunity to MV
(Lorin et al., 2005; Lorin et al., 2004). We also demonstrated that this
vector induced protective neutralizing antibodies against ﬂaviviruses
(Brandler et al., 2007; Desprès et al., 2005). A clinical development
was initiated in collaboration with an industrial vaccine manufac-
turer to evaluate the safety and immunogenicity of MV–HIV
recombinant vector in humans with preexisting immunity to
measles. This Phase I trial allows the building of GMP and regulatory
logistics for such a vaccine and will evaluate for the ﬁrst time a
replicating vector as an HIV vaccine.
In the present work, we developed a next generation of replicating
MV–HIV recombinant vectors that allow the production of fully
assembled HIV-1 virus like particles (VLP) containing trimeric
envelope glycoproteins. Since the ﬁrst use of HbS–Ag particles as an
effective vaccine against hepatitis B (Blumberg, Millman, and London,Fig. 1. Recombinant MV–HIV vectors expressing HIV-1 antigens. (A) Schematic representa
mutation in position 1 of p17 protein, the V1V2 deletion in position 130 of gp160 and the pep
into the ATU-1 and ATU-2 of MVSchw vector using BsiWI/BssHII sites. The MV genes are indi
matrix (M) fusion (F), hemagglutinin (H) and polymerase (L). T7 RNA polymerase prom
hammerhead ribozyme (hh). (B) Immunoﬂuorescence detection of HIV-1 proteins in Vero c
b–c correspond to Env labeling of permeabilized and non-permeabilized cells, respectively). (
Vero cells infected by the different rMV–HIV viruses (cell lysates are 20 times more concen1985), subviral particles have further demonstrated their human
vaccine potential with the recent marketing of the papillomavirus VLP
vaccine (Ault, 2006). HIV-1 Gag–Env VLPs (HIV-VLP) have a number
of advantages for eliciting humoral and cellular immune responses,
particularly as they present the envelope glycoproteins in an authentic
trimeric form (Hammonds et al., 2007; Ludwig and Wagner, 2007).
Moreover, HIV-1 VLPs are captured by antigen presenting cells and
efﬁciently presented to T cells by MHC molecules (Buseyne et al.,
2001). Expressed by a live replicating vector, HIV-VLPs should bud
from cells infected in vivo, thus increasing their immunogenicity
through Toll-like receptor (TLR) induction (Blander and Medzhitov,
2006; Schulz et al., 2005). We produced a series of recombinant MV
vectors expressing either HIV-1 Gag only or both Gag and Env, and
allowing or not the assembly of HIV-VLPs. We analyzed their growth
capacity and the level of HIV-VLP production. We then compared the
cellular immune responses and the neutralizing antibodies induced in
immunized-transgenic mice susceptible to MV infection. Lastly, we
evaluated their capacity to infect human antigen presenting cells
(monocyte-derived dendritic cells and B cells) and the resulting
presentation of HIV-1 antigens to both CD4 and CD8 HIV-speciﬁc T
cells.tion of HIV-1 Gag and Env constructs and of recombinant MVSchw vector. The G→A
tide signal (PS) are indicated. The HIV-1 Gag and Env sequences indicated were cloned
cated as follows: nucleoprotein (N), phosphoprotein and V/C accessory proteins (PVC),
oter (T7), T7 RNA polymerase terminator (T7t), hepatitis delta virus ribozyme (∂),
ells infected for 24 h with MV-p55Gag/Env virus (picture a is Gag labeling and pictures
C)Western blot analysis of HIV-1 proteins expression in cell lysates and supernatants of
trated than supernatants).
Fig. 2. In vitro replication of rMV–HIV viruses on Vero cells. Single-step growth curves of
recombinant MV–HIV viruses compared with empty MVSchw on Vero cells (MOI 1).
Representative experiments are shown for each virus. Vero cells on 35-mm-diameter
dishes were infected with either empty MV vector or Gag rMV–HIV viruses (A) and
Gag/Env rMV–HIV viruses (B) at an MOI of 1. The titers of cell-associated virus
recovered at each time point was determined using the TCID50 method on Vero cells.
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Generation of rMVs expressing HIV-1 Gag and Env proteins
To construct recombinant MV able to express HIV-1 VLPs, we
inserted the sequences corresponding to the HIV-1 gag and env genes
into two distinct additional transcription units (ATU) of a single pTM-
MVSchw plasmid, which contains an infectious MV cDNA correspond-
ing to the antigenome of the Schwarz MV vaccine strain (Combredet
et al., 2003) (Fig. 1A). Taking advantage of the gradient of gene
expression generated by MV replication (viral mRNAs are produced in
decreasing amounts from the 3′ to the 5′ end of MV genomic RNA
(Plumet, Duprex, and Gerlier, 2005)), we inserted the gag gene in the
ATU-1 (high expression level) and the env gene in the ATU-2 (lower
expression level). This choice was based on the observation that
mature HIV-1 particles have a low number of Env spikes on their
surface (Zhu et al., 2006) and that a high level of Gag expression is
necessary for a high amount of VLP production. Full-length (p55gag)
and truncated (p17p24gag) HIV-1 gag synthetic sequences (consensus
clade B) were generated. As a negative control unable to assemble Gag
particles, we introduced a GlyNAla substitution at the ﬁrst amino-acid
of p17p24gag (p17p24gagΔ) to abrogate myristylation, which is
essential for HIV-particle formation. The different Gag sequences
were introduced in ATU-1 of pTM-MVSchw vector. A synthetic
sequence coding for the anchored form of HIV-1 Env gp160 deleted
of the two hypervariable regions V1 and V2 (EnvΔV1V2 consensus
clade B) was generated and inserted into ATU-2 of recombinant MV-
Gag vectors. We used a delta V1V2 envelope because previous studies
showed that deletion of hypervariable loops increased the induction
of broader neutralizing antibodies as compared to wild-type form
(Kang et al., 2005; Lorin et al., 2005; Srivastava et al., 2003). In our
previous work, a triple ΔV1V2V3 mutant induced the broadest and
most potent neutralizing antibodies (Lorin et al., 2005). However,
other studies indicated that highly conserved subregions within the
V3 region are able to elicit strong neutralizing antibody responses
(Yang et al., 2004) and that the anti-V3 antibodies can neutralize
diverse strains of HIV (Zolla-Pazner et al., 2008). We decided thus to
keep the V3 region in the Env construct inserted into MV-Gag vectors.
Any other Env mutant might easily be inserted in this vector platform
in the future according to the HIV clade targeted by the vaccine
composition. These double vectors enable the production of MV–HIV
recombinant viruses expressing Gag particles coveredwith EnvΔV1V2
glycoproteins (Fig. 1A). Six recombinant viruses (MV-p55Gag, MV-
p17p24Gag, MV-p17p24GagΔ, MV-p55Gag/Env, MV-p17p24Gag/Env,
MV-p17p24GagΔ/Env) were rescued by transfecting the correspond-
ing plasmids into helper cells and propagation on Vero cells, as
previously described (Combredet et al., 2003).
rMV–HIV vectors express high levels of HIV-1 Gag and Env proteins
We detected the expression of HIV-1 proteins in cells infected by
recombinant MV–HIV vectors by immunoﬂuorescence and western
blotting (Figs. 1B, C). The Gag proteins were expressed at high level
(Fig. 1C; p17p24=41 kD; p55=55 kD), as well as the Env
glycoprotein that was cleaved in gp120 and gp41 (Fig. 1C). The
detection by immunoﬂuorescence of the gp160 Env on the surface of
non-permeabilized infected cells demonstrates that the glycoprotein
was fully processed and anchored on cell membrane through the Golgi
pathway (Fig. 1B). The high amount of inserted genetic material into
MV vector (30% of MV genome for the MV-p55Gag/Env viruses) did
not restrict MV genes expression, as shown by the similar level of MV-
N protein expressed by recombinant viruses (Fig. 1C). The stability of
transgenes expression over numerous cell passages by MVSchw
vectors has previously been demonstrated (Lorin et al., 2005; Lorin et
al., 2004). The present recombinant viruses were passaged 4 times on
Vero cells for their production.rMV–HIV vectors replicate efﬁciently
We analyzed the replication of recombinant MV–HIV vectors on
Vero cells by single-step growth curves using an MOI of 1 (Fig. 2). The
growth of recombinant viruses was similar to that of control MV and
their ﬁnal titers were comparable. Despite the presence of two
transgenes in the vector, MV–HIVGag–Env viruses had only a slight
delay in their growth and achieved the same titer than MV–HIVGag-
only recombinant viruses. MV-p55Gag and MV-p55Gag/Env viruses
grew to the same titer than parental MV vector. The efﬁcient growing
of MV-p55Gag/Env that produces high amount of HIV-1 VLPs (see
below) demonstrates that HIV particles budding does not prevent
efﬁcient MV replication. Surprisingly, MV-p17p24Gag and MV-
p17p24Gag/Env viruses grew slightly less efﬁciently than others,
suggesting that the accumulation of p17p24Gag precursors at the
inner side of the cell membrane might disturb the budding of MV
particles.
Cells infected with rMV–HIV vectors release HIV-1 Gag–Env VLPs
The expression of HIV-Gag protein is sufﬁcient to drive the process
of particle assembly and to generate the production of HIV virus-like
particles (VLPs) without the presence of other additional HIV proteins.
To analyze the effective release of VLPs from cells infected with the
Table 1
p24Gag antigen content of supernatants and cell lysates from infected cells.
p24 antigen (ng/106 cells)
MV-p17p24GagΔ/Env MV-p55Gag/Env
Supernatant (18 h) 0 2
(24 h) 0 5
(40 h) 32 185
Cell lysate (40 h) 485 218
Total 517 410
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collected cellular supernatants 36 h after infection and concentrated
them 100× by ultracentrifugation through a 20% sucrose cushion. As
shown in Fig. 1C, Gag proteins were present in the concentrated
supernatants of MV-p55Gag, MV-p17p24Gag, MV-p55Gag/Env, and
MV-p17p24Gag/Env, but not in the concentrated supernatants of MV-
p17p24GagΔ and MV-p17p24GagΔ/Env, which are unable to assem-
ble Gag particles. The Env glycoprotein was not detectable in any
concentrated supernatant (data not shown), likely because of gp120
shedding during ultracentrifugation. We also quantiﬁed by ELISA the
production of p24 antigen in supernatants and lysates of cells infected
by MV-p55Gag/Env and MV-p17p24GagΔ/Env viruses (Table 1). 40 h
post-infection, the total amount of p24 antigen produced by both
viruses was very high and similar (400–500 ng per 106 cells),
conﬁrming that mutation of the myristylation site does not affect the
total Gag-protein production (Chen et al., 2005). 46% of the total
amount of p24 produced in MV-p55Gag/Env infected cells was found
in supernatant, compared to only 6% for the particle-incompetent. At
earlier times of infection (18 and 24 h), only the supernatant from
MV-p55Gag/Env infected cells contained p24 antigen, indicating
active secretion. Moreover, as shown in Fig. 1C, theminimal amount of
p24 antigen found in supernatant of MV-p17p24GagΔ/Env infected
cells did not correspond to secreted VLPs.
The release of assembled HIV-VLPs was then analyzed by
equilibrium density centrifugation of concentrated supernatants on
20–60% sucrose gradients and detection of p24 protein by western
blot analysis of the different fractions (Fig. 3). The p24 antigen
corresponding to HIV-VLPs was found ﬂoating in the middle of the
gradient, while MV nucleoparticles (N protein) were found at the
bottom. This proﬁle corresponds to the expected densities of 1.16 for
HIV particles and 1.30 for MV.
To conﬁrm that cells infected by rMV–HIV vectors effectively
released HIV-1 Gag–Env VLPs, we performed transmission electron
microscopy observation and speciﬁc immunogold labeling 30 h after
infection (Fig. 4). Vero cells infected with MV-p55Gag and MV-
p55Gag/Env were found to intensively produce immature HIV-like
particles. These particles were so numerous that they arranged in
semicrystalline arrays around cells (Fig. 4A). Their size and morphol-
ogy were appropriate for HIV-VLPs, with a diameter of 110–130 nm
and a characteristic high density Gag layer located underneath the
viral membrane (Fig. 4B). Numerous particles were found budding
from infected cells (Figs. 4C, D). The enumeration of particles present
around cells in 10 large-scale ﬁelds allowed us to evaluate at 1500 the
number of HIV-VLPs secreted per cell in 70 nm sections. We thusFig. 3.HIV-1 virus like particles (VLP) release from rMV–HIV infected Vero cells. Western blot
cell supernatants.estimated that approximately 50,000 particles were released by a
single Vero cell. Considering this number, a T175 cell culture ﬂask
containing 20 millions MV-p55Gag or MV-p55Gag/Env infected cells
is likely to produce 1012 HIV-VLPs. The efﬁcient replication of these
particle-competent vectors (Fig. 2) demonstrates that the massive
budding of HIV particles from infected cells does not prevent MV
replication.
When MV-p55Gag/Env infected cells were immunostained with
an anti-gp120 antibody before electron microscopy observation,
numerous gold particles (10 nm diameter) were found surrounding
the Gag particles (Figs. 4E, F). This antibody labels the HIV Env spikes
anchored on the surface of particles. The average density of gold
nanoparticles was 13±6 per VLP (range 4–28, 30 VLPs were
counted). Although gold nanoparticles may also label non-trimeric
Env proteins anchored on VLPs, the low density that we observed is
close to the trimeric Env spike density previously observed by
cryoelectron microscopy tomography on wild-type HIV-1 virions
(Zhu et al., 2006).
On the other hand, Vero MV-p17p24Gag and MV-p17p24Gag/Env
infected cells did not release HIV-like particles, but were found to
produce a high amount of very large empty vesicles together with MV
particles (Fig. 4G). Some of these Gag vesicles incorporated HIV Env
gp160, as detected by immunogold staining with anti-gp120 antibody
(Fig. 4H, white arrow). We did not observe Env gold labeling
surrounding MV particles (Fig. 4H, stars), suggesting that HIV Env
glycoprotein is not able to incorporate into MV particles membrane.
This observation conﬁrms previous studies demonstrating that for
incorporating a heterologous glycoprotein on the surface of MV
particles, the transmembrane and intracytoplasmic domains need to
be swapped with those of MV glycoproteins (Spielhofer et al., 1998).
Regarding safety, this observation indicates that recombinantMV–HIV
vectors will keep the cell tropism of MV, which is broader than HIVs.
Lastly, the empty MV vector induced the production of standard MV
particles with an average size of 150–350 nm (Fig. 4I). In these
particles, the genomic ribonucleoparticle was clearly noticeable
(particle with a star in Fig. 4I).
Immunization of mice with rMV–HIV vectors
To select the most immunogenic candidate before evaluating its
efﬁcacy in a non-human primatemodel of HIV infection, we compared
the ability of the different rMV–HIV vectors to raise speciﬁc anti-MV
and anti-HIV antibody and cellular responses in genetically modiﬁed
mice susceptible to MV infection (Mrkic et al., 1998). These mice
express CD46, the human receptor for vaccineMV strains, and lack the
INF-α/β receptor (IFNAR). They are commonly used as a preclinical
model to evaluate the immunogenicity of recombinant MV before
non-human primates experiments (Brandler et al., 2007; Combredet
et al., 2003; Desprès et al., 2005; Liniger et al., 2008; Lorin et al., 2005;
Lorin et al., 2004; Singh, Cattaneo, and Billeter, 1999; Zuniga et al.,
2007). Six-week-old CD46-IFNAR mice (6 mice per group) received
106 TCID50 of the different rMV–HIV vectors by intraperitoneal (ip)
injection at days 0 and 28. As a control, CD46-IFNAR mice were
immunized similarly with empty MV vector.analysis of sucrose gradient fractions obtained after ultracentrifugation of infected Vero
Fig. 4. Electron microscopy analysis of HIV-1 VLP formation. Ultrathin-section electron microscopic analysis of Vero cells infected with the different recombinant MV–HIV viruses, as
indicated. In pictures E, F and H, anti-HIV-1 Env gold immunostaining with 10-nanometer colloidal gold particles was performed. The arrow in picture H indicates a large p17p24
vesicle stained by anti-Env immunogold. The star in picture I shows a MV particle, with genomic ribonucleoproteins inside. Magniﬁcations are variable between 35,000 and 115,000.
Bars indicate the scale.
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We looked for antibodies raised speciﬁcally to MV and to HIV Gag
and Env in mice sera before immunization, 1 month after the ﬁrst
injection, and also 3 weeks and 11 weeks after the second injection
(Fig. 5). Antibodies to MV were induced at similar levels in all
immunized mice. The ﬁrst injection induced MV antibodies with
limiting dilution titers of about 104 and the boost increased these
titers 10 times. A persisting antibody memory response to MV was
observed 15 weeks after the ﬁrst immunization, with titers stabilized
between 104 and 105, as previously described (Lorin et al., 2004) (Fig.
5A). Anti-Gag antibodies were induced at high level in all mice (titers
of 105–106 after boost, remaining above 105 at 15 weeks post prime)
(Fig. 5B). Anti-Env antibodies were induced in all mice that received
rMV–HIV expressing HIV Env (Fig. 5C). A single injection of both MV-
p55Gag/Env and MV-p17p24Gag/Env vectors was sufﬁcient to raise
titers up to 104, and the second injection increased only marginally
these titers that remained at the same level over time up to 15 weeks
post priming. On the other hand, the particle-incompetent MV-
p17p24GagΔ/Env vector induced a much lower titer of anti-Env
antibodies after the ﬁrst injection (102), and boostingwas necessary to
increase titer to a level that remained below 104 at 15 weeks after
priming. This difference could be due to a different level of Env protein
expressed by the vectors. However, although MV-p55Gag/Env vector
expressed a higher level of Env, as observed in Fig. 1C, both MV-
p17p24Gag/EnvandMV-p17p24GagΔ/Env vectors expressed a similar
level (Fig. 1C). Moreover, the 3 Env-expressing vectors had a similarimmunogenicity to MV and to Gag (Figs. 5A and B), and only the
particle-incompetent vector had a lower immunogenicity to Env. This
result demonstrates that expressing Env onto secreted particles allows
achieving a higher titer of anti-Env antibodies after a single injection.
rMV–HIV expressing HIV-1 Gag–Env VLPs induces neutralizing
antibodies
As a preliminary test of functionality, we evaluated the capacity of
sera from immunized mice to neutralize a heterologous clade B HIV-1
primary isolate (Bx08 virus, NIH) in a single-cycle virus infectivity
assay on P4C5 indicator cells (Barin et al., 2004; Lorin et al., 2004).
P4C5 cells express the CD4, CXCR4 and CCR5 HIV-1 receptors and have
been stably transfected with an HIV LTR-LacZ construct. Therefore,
they are susceptible to HIV-1 isolates and express β-galactosidase
upon infection. The sero-neutralization assay was validated using a
combination of anti-HIV immunoglobulin (HIVIG, 2.5 mg/ml) and
monoclonal antibodies (2F5 and 2G12, 25 μg/ml each) that were
previously shown to synergistically neutralize primary HIV isolates
(Mascola et al., 1997). We assessed the neutralizing activity induced in
immunized mice on 1/30 dilutions of sera collected 15 weeks after
priming. To take into account the non-speciﬁc HIV-1 inhibition by
mouse serum and the possible effects of Gag antibodies, the 100% level
of infectivity was determined in the presence of the same dilution of a
mix of sera from mice immunized with vectors expressing Gag only.
The neutralizing activity was expressed as the percentage of inhibition
of infection observed in the presence of the sample sera compared to
Fig. 5. Antibody response induced in mice immunized with rMV–HIV viruses. Mice
were immunized with the different vectors as indicated and sera were collected before
priming, 1 month after priming, then at 3 and 11 weeks after boosting. The data show
the reciprocal endpoint dilution titers of speciﬁc antibodies to MV (A), HIV-1 Gag (B)
and Env (C). (D) HIV-1 neutralization activity of sera from immunized mice.
Neutralization of heterologous BX08 clade B primary virus by sera collected from
immunized mice 11 weeks after boosting. Neutralization values are expressed as the
percentage of inhibition of P4C5 cells infection by HIV-1 in the presence of sera from
immunized mice. The 100% infection was determined in the presence of the same
dilution of sera from control mice. The 100% of neutralization (Mab) was obtained in
presence of a mix of neutralizing monoclonal antibodies 2F5 and 2G12 plus anti-HIV
IgG. Results are presented as the mean values of three independent in vitro
neutralization experiments performed in triplicate with pooled sera from 6 immunized
mice per point±standard deviation.
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combination neutralized more than 90% of infectivity in this assay,
as previously observed (Lorin et al., 2004), and no inhibition of
infection was observed with sera from mice immunized with empty
MV vector, showing that anti-MV immunity did not neutralize HIV
non-speciﬁcally. The sera from mice immunized with rMV–HIVGag/
Env vectors were able to neutralize the infection with various
efﬁciencies. The particle-incompetent vectors induced only a weak
neutralizing activity, while the highest neutralizing activity (around70%) was observed with sera from mice immunized with MV-
p55Gag/Env. Similar neutralizing titers were observed against Bx08
virus in our previous studies with MV vectors expressing HIV Env only
(Lorin et al., 2005; Lorin et al., 2004). However, in these previous
studies the Env sequence was inserted in ATU-1 of MV vector, which
induces a 10 times higher level of expression than the ATU-2 used for
Env expression in the present study (Plumet, Duprex, and Gerlier,
2005). This result indicates that, in the context of a replicatingmeasles
vector, HIV-1 Env is more immunogenic when expressed onto
assembled Gag VLPs, even despite a lower expression level. To express
simultaneously Gag and Env from the same vector and to favor the
production of high amounts of Gag VLPs, we choose in this study to
insert Gag in ATU-1 and Env in ATU-2. In a next construct the reverse
situation will be evaluated. This promising result needs to be
conﬁrmed with other Env constructs in a non-human primate
model, which is more appropriate for neutralizing antibodies.
rMV–HIV vectors induce cellular immune responses to HIV
We then looked for cellular immune responses raised speciﬁcally
against MV and HIV Gag and Env epitopes both at 1 and 15weeks after
priming. As a quick and simple test, we used enzyme-linked
immunospot (ELISPOT) assay to evaluate the capacity of splenocytes
from immunized mice to secrete IFN-γ in response to a speciﬁc
stimulation with either UV-inactivated MVSchw virus or HIV-1 Gag
and gp160 peptide pools (Fig. 6). The level of MV-speciﬁc T cell
response was high after priming (1300–1800 spots/106 cells) and
remained still high after 15 weeks (900–1600 spots/106 cells)
showing that a single immunization induced a saturated response.
On the contrary, the ELISPOT response to HIV-1 Gag and Env increased
with time. Again, the MV-p55Gag/Env vector expressing HIV-1 Gag–
Env VLPs was the most immunogenic and induced a strong T cell
response both to Gag (1200 spots/106 cells) and to Env (400 spots/
106 cells). The global level of ELISPOTs raised by this vector against
HIV-1 (1800 spots/106 cells) was similar to the level raised against
MV. These responses were detected 15weeks after priming, indicating
that memory was established, as for antibodies. The presence of Env
gp160 expressed onto Gag p55 VLPs increased signiﬁcantly the
ELISPOT response to Gag, suggesting a cross presentation mechanism
due to a better capture of HIV-1 Gag/Env particles than HIV-1 Gag
only particles by antigen presenting cells.
The strong capacity to raise T cell responses that persist on long
term in lymphoid organs is a hallmark of live attenuated vaccines. MV
is particularly efﬁcient at generating live long memory CD4 and CD8 T
cells that help to maintain neutralizing antibodies and to prevent from
reinfection (Naniche et al., 2004; Ovsyannikova et al., 2003). A
number of studies have shown that a strong CD8 Tcell response to HIV
Gag reduces the chronic as well as the primary viral load in macaques
and even protects from a heterologous SIV challenge (Reynolds et al.,
2008). As well, the long-term control of SIV replication in vaccinated
macaques has been correlated to the preservation of central memory
CD4 T cell (Kawada et al., 2007). The induction of strong and long-
term CD4 and CD8 T cells to Gag is thus a major component of an HIV
vaccine. HIV VLPs have long been shown to stimulate speciﬁc T cell
responses (Buonaguro et al., 2002; Wagner et al., 1996). Our results
show that the in vivo expression of HIV VLPs through a safe live
replicating MV vaccine induces the persistence of a strong T cell
response. This advantageous characteristic of MV is likely due to its
property to infect dendritic cells and to propagate to T cells, as HIV
does.
rMV–HIV vectors infect human DC and B cells, and allow MHC-I and -II
restricted antigen presentation
We then explored the capacity of these vectors to present HIV-1
epitopes to human T cells in vitro. Human dendritic cells (DCs) are
Fig. 6. T cell responses induced in mice immunized with rMV–HIV viruses. IFN-γ ELISPOT analysis of MV and HIV-1 speciﬁc T cell responses stimulated in mice immunized with the
different vectors as indicated. Splenocytes were collected 1 and 15 weeks after priming (grey and black bars, respectively) and restimulated with either UV-inactivated MV or HIV-1
speciﬁc peptides for 40 h. Results are expressed as number of spots per million cells. Results are presented as the mean values obtained from 6 mice performed in triplicate each
±standard deviation.
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regulation of co-stimulatory molecules (Klagge, ter Meulen, and
Schneider-Schaulies, 2000; Schnorr et al., 1997; Servet-Delprat et al.,
2000). Upon virus infection, immature DCs undergo maturation and
transport the virus to regional lymph nodes, where viral antigens
are presented to lymphocytes to initiate immune response (Ban-
chereau and Steinman, 1998). To evaluate the ability of rMV–HIV
vectors to induce class-I or class-II presentation of HIV-1 epitopes in
a human system, we performed a previously described in vitro
antigen presentation assay (Moris et al., 2004; Moris et al., 2006),
using HIV-speciﬁc CD4 and CD8 human T cell clones and HLA-
matched human APCs (Fig. 7). Because of limited HLA-matching
possibilities, we used DCs for presentation to CD8 cells and B-cells
for presentation to CD4 cells. Monocyte-derived DCs and EBV-
transformed human B-cells (B-EBV) were infected with rMV–HIV
vectors at different MOIs. The production of p24 antigen in infected
cells was quantiﬁed by ﬂow cytometry 24 h post-infection. DCs
were highly susceptible to rMV–HIV vectors, even at very low MOIs,
and the particle-incompetent vectors MV-p17p24GagΔ and MV-
p17p24GagΔ/Env produced twice as much p24 in DCs than p55Gag-
expressing vectors (Fig. 7A1). Higher MOIs were required for
efﬁcient infection of B cells and MV-p17p24GagΔ/Env produced
the highest level of p24 (Fig. 7B1). After 24 h of infection, infected
DCs and B-EBV were co-cultivated for additional 18 h with
autologous HLA-matched CD4+or CD8+ HIV-1-speciﬁc T cell clones:
infected DCs were co-cultivated with the HLA-A2-restricted CD8+ T
cell clone EM40 speciﬁc of HIV-1 Gag–p1777–85 SL9 epitope, and
infected B-EBV were co-cultivated with the HLA-DRβ⁎01-restricted
CD4+ T cell clone F12 speciﬁc of HIV-1 Gag–p24271–290 gag2 epitope
(Moris et al., 2004; Moris et al., 2006). Then, the number of IFN-γ
secreting CD4+ and CD8+ T cells was quantiﬁed by ELISPOT.
We ﬁrst observed that viral replication was required for efﬁcient
speciﬁc T cell activation, as UV-inactivated viruses did not induce any
ELISPOT (Figs. 7A2 and B2). Mock-infected cells and cells infectedwith
empty MVSchw vector (not shown) did not stimulate Gag-speciﬁc T
cells. When DCs and B-EBV were exposed to increasing MOI of rMV–
HIV viruses, the activation of Gag-speciﬁc T cells was dose dependent
(Figs. 7A2 and B2), except for MV-p55Gag virus in DCs and MV-
p17p24GagΔ/Env virus in B-EBV. In these cases, the maximum
activation was already achieved with the lowest MOI, likely reﬂecting
a better presentation of Gag epitopes by infected cells. To estimate the
efﬁciency of epitope presentation relatively to the number of infected
presenting cells, we divided the number of IFN-γ positive spots by the
percentage of Gag-positive DC or B cells. At the lowest MOI tested(0.01 for DCs and 0.2 for B cells), the result shows that vectors
expressing p55Gag VLPs were about 5 times more efﬁcient for Gag-
speciﬁc CD8+ T cells activation by DCs than particle-incompetent
vectors (Fig. 7A3). At higher MOIs, this difference diminished but the
tendency remained the same (not shown). In B cells, vectors
expressing the Env were twice as efﬁcient for Gag-speciﬁc CD4+ T
cell activation at the lowest MOI (Fig. 7B3), but this observation was
not conﬁrmed at higher MOIs. In conclusion, these results demon-
strate that replicating rMV–HIV vectors infect human professional
antigen-presenting cells (DCs and B-cells) and induce efﬁcient
presentation of HIV-1 epitopes to HLA-matched T cells and subse-
quent activation of cytokine secretion.
Discussion
Live attenuated vaccines are the most appropriate for global mass
immunization. They induce long-term protection because they
replicate in vivo after administration. They are easy to multiply
because they replicate in vitro in cell culture. Although a live
attenuated HIV vaccine is not currently considered for safety reasons,
a strategy inducing both T cells and neutralizing antibodies to native
assembled HIV particles expressed by a replicating virus might mimic
the protective characteristics of live attenuated SIV (Koff et al., 2006).
In this work, we generated a live attenuated measles vaccine
expressing HIV-1 Gag VLPs covered with gp160ΔV1V2 and demon-
strated its capacity to induce at long-term a high level of antibody
with neutralizing activity, as well as a strong T cell immune response
to both Gag and Env epitopes. This strategy provides a recombinant
vaccine that might protect children and adolescents simultaneously
from measles and HIV and be affordable to populations through the
Expanded Program on Immunization of WHO in the regions affected
both by HIV and measles infections.
Live attenuated virus vaccines, such as those against mumps,
measles, polio and rubella viruses induce both cell-mediated and
humoral immunity. Protection is afforded by the stimulation of
polyclonal neutralizing antibodies, and memory is maintained
through an efﬁcient cellular immunity. For the chronic and highly
variable HIV-1, the ability to induce broadly neutralizing antibodies
and long-term protective memory through vaccination has been a
discouraging task for several years. The hallmark of HIV-1 is its
capacity to establish chronic infection and to generate tremendous
viral genetic diversity, mostly in the only proteins present on the virus
surface, gp120/gp41 that evolved many mechanisms to evade host
neutralizing responses (Burton et al., 2004; Wei et al., 2003).
Fig. 7. Infection of human DCs and B cells by recombinant MV–HIV viruses, and MHC-I and MHC-II-restricted antigen presentation. DCs (A) and B cells (B) were infected at the
indicated MOI. 24 h post-infection, a part of the cells were ﬁxed and stained for HIVp24Gag expression (1). The remaining cells were co-cultivated with anti-Gag speciﬁc HLA-
matching CD8+ (A) or CD4+ (B) T cells for 24 h before IFNγ ELISPOT analysis of T cell responses. The data are shown as the number of IFNγ positive cells for 2500 T cells (mean value
from triplicatewells±standard deviation) (2) and as the ratio of IFNγ positive spots related to the percentage of p24Gag positive DCs or B cells determined at the lowest MOI (3). The
negative control of infection (NI) was mock-infected DCs or B cells. Results are presented as the mean values of three independent experiments performed in triplicate±standard
deviation.
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harboring a large set of HIV-1 variants that continue to spread and
evolve in the human population, providing protection through
vaccination appears an enormous challenge. However, current models
predict that if vaccination could substantially lower the level of acute
viraemia or reduce the chronic “set point” in an individual, then the
transmission rate in the population would be reduced (Davenport et
al., 2004). Therefore, vaccine strategies able to stimulate long-term
polyclonal neutralizing antibodies to the most conserved parts of the
HIV-1 Env, together with strong cellular immunity composed of bothCD4+ and CD8+ T cells directed also to the most conserved viral
epitopes, need to be further worked out.
With this aim, we derived a vector from the most safe and
efﬁcacious pediatric live attenuatedmeasles vaccine and developed its
use as a bivalent recombinant vaccine to immunize simultaneously
against measles and other infectious diseases (Combredet et al.,
2003). This vector demonstrated a strong capacity to stimulate both
cellular and humoral neutralizing immunity against a number of
antigens in several animal models (Brandler et al., 2007; Brandler and
Tangy, 2008; Desprès et al., 2005; Lorin et al., 2005; Lorin et al., 2004;
199M. Guerbois et al. / Virology 388 (2009) 191–203Tangy and Naim, 2005). The strong immunogenicity of MV is likely
due to its capacity to infect productively human professional antigen-
presenting cells, such as macrophages, dendritic cells and B cells.
Using MV as a vaccination vector presents a number of advantages:
the mandatory global vaccination against measles is still needed for a
foreseeable future, vaccine strains are genetically stable, MV does not
recombine or integrate genetic material, vaccine does not persist or
diffuse, MV-speciﬁc CD8 Tcells and IgG are detected in vaccinees up to
25–34 years after a single MV vaccination (Grifﬁn, 2001; Naniche et
al., 2004; Ovsyannikova et al., 2003) and boosting increases this
memory (Ovsyannikova et al., 2003). The remarkable stability of
transgenes expression by single-stranded negative RNAviruses results
from the absence of geometric constraints on the size of the genome in
these pleomorphic viruses with helicoidal nucleocapsids (Schnell et
al., 1996 2197) and allows the use of MV vector as a platform to
express large amounts of foreign genes.
In this work, we generated replicating MV–HIV recombinant
vaccine expressing HIV-1 VLPs covered with envelope glycoproteins,
and evaluated its preclinical immunogenicity. VLPs have been
explored as HIV-1 vaccine candidates for several years (Doan et al.,
2005; Ludwig and Wagner, 2007; Young et al., 2006) and have
demonstrated their immunogenicity (Deml et al., 2005). However,
most of the evaluated strategies are based on repeated administra-
tions of high doses of VLPs produced in vitro in heterologous systems,
as insect cells (Buonaguro et al., 2001; Wagner et al., 1992; Yao et al.,
2000) or yeast (Sakuragi et al., 2002). Other delivery strategies used
non-replicative canarypox vectors (Fang, Kuli-Zade, and Spearman,
1999; Hammonds et al., 2007) or naked DNA (McBurney et al., 2006;
Young, Smith, and Ross, 2004), for which, again, a high number of
administrations are necessary. Live replicating MV vector allows
massive in vivo production and diffusion through the organism of
VLPs at the time of vaccination.
We generated rMV–HIV viruses expressing HIV-1 Gag and Env
proteins able to assemble a high amount of VLPs with gp160 spike
density very close to that of wild-type HIV-1 virions (Zhu et al.,
2006), thanks to the gradient of gene expression generated by MV
replication (Plumet, Duprex, and Gerlier, 2005). The versatility of
this vector allows generating further constructs in which the gag
and env genes can be ﬂipped over to increase the spike density on
VLPs, although it would probably lower the yield of VLP production.
We produced six rMV–HIV vectors expressing different forms,
secreted or not, of p17p24 or p55 Gag antigens with or without
gp160ΔV1V2. The vectors replicated efﬁciently in cell culture,
demonstrating that MV and HIV particles can bud simultaneously
without interference from infected cells, and they produced very
high amounts of Gag antigen. HIV-1 VLPs were secreted efﬁciently
from cells infected with MV-p55Gag/Env virus. In electron micro-
scopy a huge number of HIV-1 particles were found budding from
infected cells or surrounding them. Immunogold labeling demon-
strated the presence of Env spikes at the surface of VLPs with an
average density of 13±6 per particle. The heterologous HIV Env
glycoprotein did not incorporate into MV particles. Regarding the
safety of such live recombinant vaccine, this observation indicates
that MV cell tropism will be conserved, although MV readily infects
all HIV target cells.
In mice sensitive to MV infection, these vectors stimulated a high
level of antibodies that persisted up to 15 weeks after immunization.
Anti-HIV Gag antibodies were raised at similar titers than anti-MV
antibodies. Anti-Env antibodies were also induced at high titer after a
single injectionwith MV-p55Gag/Env virus, demonstrating the better
immunogenicity of HIV-1 Env glycoprotein inserted into Gag particles.
Although at moderate titer, these antibodies neutralized a hetero-
logous clade B HIV-1 primary isolate. On the contrary, sera from mice
immunized with vectors expressing Gag VLPs without Env slightly
enhanced HIV infection in vitro. It is tempting to speculate that a
vaccine strategy based on the expression of Gag VLPs without Envmight induce enhancement of infection. MV is known to stimulate a
persisting mucosal immunity that protects from a disease transmitted
through mucosa. If such neutralizing antibodies are present on the
mucosal sites of HIV-1 infection, they will help to control the ﬁrst
steps of infection (Miller and Abel, 2005; Miller et al., 2005). A
humoral response composed of IgG and IgA has been evidenced in
exposed non-infected individuals (Buchacz et al., 2001; Devito et al.,
2000), and the presence of speciﬁc IgA has recently been associated to
HIV-1 resistance in Kenyan sex workers (Hirbod et al., 2008).
The rMV–HIV viruses also stimulated a strong cellular immunity
that persisted up to 15 weeks. The magnitude of the response against
HIV-1 Gag and Env proteins was identical to that against MV, as
enumerated by ELISPOT. Again, the MV-p55Gag/Env vector was the
most immunogenic, reﬂecting the high level of Gag/Env VLPs
expressed. Lastly, we demonstrated that rMV–HIV vectors infect
human professional antigen-presenting cells (DCs and B-cells) and
induce efﬁcient presentation of HIV-1 epitopes to HLA-matched T
cells. The subsequent activation of cytokine secretion by human HIV-1
Gag-speciﬁc T cell clones demonstrates the immunogenic potential of
these recombinant vectors in humans. The efﬁcient release and re-
uptake of HIV-1 VLPs by DCs infected with MV-p55Gag/Env vector
likely induced cross-presentation of captured VLPs, thus increasing
the standard class-I presentation of HIV-1 antigens produced in
infected DCs and resulting in an efﬁcient CD8+ activation. Replication
of the vectors was required to induce activation. MV-infected DCs
induce cell apoptosis in neighboring cells (Fugier-Vivier et al., 1997).
This activity is mediated by the secretion of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), which is induced by MV
replication (Vidalain et al., 2000). Cross-presentation by dendritic
cells to CD8+ T cells of very small amounts of HIV proteins from
apoptotic infected CD4+ T lymphocytes is very efﬁcient (Maranon et
al., 2004). This suggests a mechanism by which DCs infected by rMV–
HIV increase the presentation of HIV antigen to CD8+ T cells.
In conclusion, we demonstrated that a recombinant measles
vaccine expressing a high level of fully assembled HIV-1 VLPs covered
with gp160ΔV1V2 can be produced at high titers. This MV-p55Gag/
Env vaccine candidate was strongly immunogenic in a mouse
preclinical model of infection and deserves to be tested in non-
human primates. If better Env immunogens capable of inducing
broadly neutralizing antibodies to a large variety of HIV-1 quasi-
species are obtained eventually, they will be easily included into this
vector, thus providing a human HIV vaccine platform with numerous
potential advantages.
Materials and methods
Cell culture
Vero cells (African green monkey kidney cells) were maintained
in DMEM-Glutamax (Gibco-BRL) supplemented with 5% heat-
inactivated fetal calf serum (FCS, Invitrogen, Frederick, MD). Stable
helper 293-T7-NP cells were previously generated by transduction
with recombinant lentiviral vectors and cloning (Tangy, Charneau,
and Jacob, 2006). They were used for viral rescue and grown in
DMEM 10% FCS. P4C5 indicator cells (HeLa, CD4+, CXCR4+, CCR5+,
HIVLTR–LacZ+) (Marechal et al., 1998) were cultured in DMEM 10%
FCS supplemented with 0.5 mg/ml G418 (Geniticin; Gibco) and
50 μg/ml Hygromycine (Calbiochem). Clinical-grade DCs were
prepared as described elsewhere (Goxe et al., 1998; Moris et al.,
2006) and maintained in AIMV medium containing 500 U/mL GM-
CSF (Gentaur, Brussels, Belgium) and 50 ng/mL IL-13 (Peprotech,
Tebu-bio, Rocky Hill, NJ). The EM40 HIV-1-speciﬁc CD8+ T cell
clone, the F12 HIV-1-speciﬁc CD4+ T cell clone, the EBV-immorta-
lized B cells and monocyte-derived dendritic cells were grown in
RPMI 10% FCS supplemented with IL-2 (100 U/ml) (Moris et al.,
2004; Moris et al., 2006).
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The plasmid pTM-MVSchw, which contains an infectiousMV cDNA
corresponding to the anti-genome of the Schwarz MV vaccine strain,
has been described elsewhere (Combredet et al., 2003). Consensus
codon-optimized HIV-1 clade B sequences coding for the full-length
p55Gag or truncated p17p24Gag polyproteins, and for the EnvΔV1V2
envelope glycoprotein, were synthesized (GeneArt) and ampliﬁed
from plasmid with primers containing unique BsiWI and BssHII sites
for subsequent cloning in MV vector (Fig. 1). The p17p24gag sequence
was modiﬁed to create the p17p24GagΔ protein, incompetent for the
formation of Gag-particles. Brieﬂy, directed mutagenesis was per-
formed on the p17p24gag sequence to introduce a glycine-to-alanine
mutation in the N-terminal myristylation site of the protein. All the
constructs cloned in pCR2.1-TOPO plasmid (Invitrogen) were
sequenced. They respect the “rule of six”, which stipulates that the
number of nucleotides of MV genomemust be amultiple of six (Calain
and Roux, 1993). The sequences corresponding to p55Gag, p17p24Gag
and p17p24GagΔ were introduced in ATU-1 of pTM-MVSchw vector
after BsiWI/BssHII digestion. The resulting plasmids were designated
pTM-MV-p55Gag, pTM-MV-p17p24Gag and pTM-MV-p17p24GagΔ.
The sequence corresponding to EnvΔV1V2was then inserted in ATU-2
of each MV-Gag vector. The resulting vectors were designated pTM-
MV-p55Gag/Env, pTM-MV-p17p24Gag/Env and pTM-MV-
p17p24GagΔ/Env. All constructs were veriﬁed by complete
sequencing.
Rescue of recombinant MV-Gag and MV-Gag/Env viruses
Recombinant MV–HIV viruses were recovered from the pTM-MV-
Gag and pTM-MV-Gag/Env plasmids using a helper-cell-based rescue
system (Tangy, Charneau, and Jacob, 2006) that was similar to that
developed by Radecke et al. (1995) and modiﬁed by Parks et al.
(1999). The titers of recombinant MV were determined by an
endpoint dilution assay on Vero cells. Brieﬂy, Vero cells were seeded
into 96-well plates (7500 cells/well) and infected by serial 1:10
dilutions of virus sample in DMEM–5% FCS. After incubation for 7 days,
cells were stained with crystal violet and the TCID50 values were
calculated by use of the Karber (1931) method.
Virus growth curves
Monolayers of Vero cells in 35-mm-diameter dishes were infected
with viruses at multiplicity of infection of 1 (MOI 1). At various times
post infection cells were scraped into culture medium. After freeze-
thawing of cells and medium and clariﬁcation of cell debris, virus
titers were determined on Vero cells as described above.
Immunoﬂuorescence
To detect the expression of proteins, immunoﬂuorescence stain-
ing was performed on infected VERO cells ﬁxed with 4% paraformal-
dehyde (PFA) in PBS. Cells were incubated 1 h in blocking solution
(PBS 2% Goat Serum), permeabilized or not with 0.1% Saponine in
PBS, and probed with a mouse anti-HIVp24 monoclonal antibody
(23A5; kindly provided by Bernard Verrier, Lyon) or a human
monoclonal anti-HIVgp120 antibody (2G12; NIH-AIDS Research and
Reference Reagent Program). A Cy3-conjugated goat anti-mouse IgG
antibody and a Cy3-conjugated goat anti-human IgG antibody
(Jackson Immunoresearch laboratories) were used respectively as
secondary antibodies.
Western blots assays
Vero cells were infected with MV–HIV recombinant viruses at a
multiplicity of infection (MOI) of 1. Protein lysates or 100X-concentrated supernatants were fractionated by SDS-PAGE gel
electrophoresis on 4–12% Nupage Bis–Tris gels with MOPS running
buffer (Invitrogen) and transferred to cellulose membranes with the
IBlot Dry blotting system (Invitrogen). To detect HIV and MV proteins,
the membranes were blotted with either a mouse anti-HIVp24 mAb
(23A5; kindly provided by Bernard Verrier, Lyon), a cocktail of anti-
HIVEnv gp120 and gp41mAbs (160A+ 41A+ 110HmAbs; Hybridolabs,
Institut Pasteur, Paris), or a mouse anti-MV N mAb (clone 120; kindly
provided by Dr Chantal Rabourdin-Combe, Lyon, France). A goat anti-
mouse IgG-horseradish peroxidase (HRP) conjugate (Amersham) was
used as a secondary antibody. Peroxidase activity was visualized with
an enhanced chemiluminescence detection kit (Pierce).
Analysis of VLP production by sucrose gradient puriﬁcation
Vero cells (3 T–150 ﬂasks) were infected with either empty MV
vector or MV–HIV recombinant viruses at MOI 1. Supernatants
collected after 36 h of infection were clariﬁed by centrifugation at
3000 rpm for 30 min, layered on 20% sucrose cushion in PBS and
centrifuged at 41,000 rpm for 2 h in a SW41 rotor. Pellets were
resuspended in PBS 1% BSA and applied on the top of a 20% to 60%
sucrose gradient, followed by centrifugation in a SW41 rotor for 16 h at
28,000 rpm. Fractions (1ml)were collected and the protein content of
each fractionwas analyzed by SDS-PAGE followed by immunoblotting,
as described above.
Electron microscopy and gold immunostaining
Vero cells were seeded on cover glass strips and infected at a
MOI of 1 with the different MV–HIV recombinant viruses. Cells were
ﬁxed 30 h post-infection with 2% PFA in PBS for 5 min and with 4%
PFA for 2 h at room temperature. Non-speciﬁc sites were saturated
for 10 min with 1% bovine serum albumin and cells were probed for
40 min with anti-HIVgp120 antibody (2G12; NIH-AIDS Research and
Reference Reagent Program) in PBS–1% BSA. After washing, cells
were incubated for 20 min with 10-nanometer colloidal gold
particles coated with protein A (University Medical Center, Utrecht).
Stained cells were then ﬁxed in 2.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer overnight at 4 °C, postﬁxed with 1% osmic acid,
dehydrated in ethanol, and embedded in Epon. Ultrathin sections of
70–80 nm were cut with a diamond knife, stained with uranyl
acetate and Reynolds lead citrate, and observed at 80 kV accelerat-
ing voltage using JEOL JEM 1010 Electron Microscope and an Eloïse
Mega View III camera. Control, uninfected Vero cells were included
in this analysis.
Animal immunizations
CD46-IFNAR mice susceptible to MV infection were produced as
previously described (Combredet et al., 2003). These mice express the
human CD46 gene with human-like tissue speciﬁcity, within addition,
a target mutation inactivating the interferon receptor type I (Mrkic et
al., 1998). Mice were housed under speciﬁc pathogen-free conditions
at the Pasteur Institute animal facility and all experiments were
approved and conducted in accordance with the guidelines of the
Ofﬁce of Laboratory Animal Care at Pasteur Institute. Six-week-old
CD46-IFNAR mice were inoculated intraperitoneally (ip) with 1×106
TCID50 of MV–HIV recombinant viruses and boosted 1 month later
with the same dose of recombinant viruses. Control mice were
immunized with the same dose of empty MVSchw vector. For early
cellular immune responses analysis, mice were euthanized at 7 days
post-immunization and spleens were collected. For antibody
determination, blood samples were collected via the periorbital
route 1 month after the ﬁrst inoculation, then at 3 and 11 weeks
after boosting. To analyze long-term cellular responses, mice were
euthanized 11 weeks after boosting and spleens were collected.
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Sera collected from immunized mice were heat-inactivated for
30 min at 56 °C and the presence of anti-MV, anti-HIVGag and anti-
HIVEnv antibodies was assessed using enzyme-linked immunosor-
bent assay (ELISA). A commercial ELISA kit (Trinity Biotech) was
used for anti-MV antibody detection. For anti-HIV antibodies, 96-
well plates were coated with either HIV-1 p24 antigen (Jena
Bioscience) or HIVBAL gp120 recombinant protein (NIH AIDS
Research and Reference Reagent Program) diluted in carbonate
buffer pH 9.6 at a concentration of 1 μg/ml. The plates were
incubated overnight at +4 °C and washed with PBS–0.05% Tween
20 (PT). Unspeciﬁc interactions were blocked with 1% BSA in PBS for
1 h at 37 °C. After washing, plates were incubated with serial
dilutions of mouse sera for 90 min at room temperature. Horse-
radish peroxidase-conjugated goat anti-mouse IgG (Jackson Immu-
noresearch laboratories) was used as secondary antibody and plates
were revealed with TMB substrate (Pierce). The endpoint titers for
each individual serum were calculated as the reciprocal of the last
dilution giving twice the absorbance (450 nm) of sera from MV
inoculated mice that served as negative control.
HIV-1 neutralization assay
Seroneutralization was tested against the clade B HIV-1 primary
isolate Bx08 (NIH-AIDS Research and Reference Reagent Program).
HIV-1 neutralization assays were performed by using the P4C5
indicator cell line (Marechal et al., 1998) as previously described
(Barin et al., 2004; Lorin et al., 2004). Brieﬂy, P4C5 cells were seeded
into 96-well plates (20,000 cells per well) and incubated for 24 h at
37 °C in DMEM–10% FCS supplemented with hygromycin plus G418.
The medium was replaced with 30 μl of DMEM–10% FCS-DEAE
Dextran (10 μg/ml) and cells were incubated for 30 min at 37 °C. HIV-
1 virus Bx08 (0.5 ng of p24 per well) was incubated with 1:30 diluted
mice sera in 30 μl of FCS-free culture medium at 37 °C for 45 min and
the virus–serum mixtures were added to the cells in triplicate. 100 μl
of DMEM–10% FCS were added to each well 2 h later. After 48 h of
incubation, the β-galactosidase activity was measured using a
chemiluminescent reporter gene assay (Roche). The mean neutraliza-
tion for each serum tested was reported to the value recorded in wells
containing control serum from non-immunized (NI) mice at the same
dilution that served as reference for 100% infection. A mix of
neutralizing monoclonal antibodies (Mab) 2F5 and 2G12 (25 μg/ml
each; NIH-AIDS Research and Reference Reagent Program) plus anti-
HIV IgG (2.5 mg/ml; NIH-AIDS Research and Reference Reagent
Program) was used as a positive control of neutralization.
Cellular immune responses
The capacity of splenocytes from immunized mice to secrete
IFN-γ upon speciﬁc stimulation was tested by enzyme-linked
immunospot (ELISPOT) assays. Multiscreen-HA 96-well plates
were coated overnight at +4 °C with 5 μg/ml of anti-mouse
IFN-γ (BD Pharmingen) in carbonate buffer 50 mM pH 9,6. After
washing, unspeciﬁc sites were blocked for 2 h at 37 °C with RPMI–
10% FCS. The medium was then replaced by 100 μl of cell
suspension (1×106 splenocytes/well in triplicate) and 100 μl of
stimulating agent in complete RPMI, and plates were incubated for
40 h at 37 °C. Cells were stimulated with either SEB (Staphylo-
coccal enterotoxin B, Sigma 2 μg/ml) as positive control, complete
RPMI (RPMI–5% FCS supplemented with non-essential amino-acids
1%, sodium pyruvate 1% and β-mercaptoethanol) as negative
control, a mixture (2 μg/ml each) of HIV-1 Gag (15-mer) or HIV-
1 gp160 (20-mer) peptides (NIH-AIDS Research and Reference
Reagent Program), or UV-inactivated MVSchw virus (1 TCID50 per
cell). After incubation and washing, biotinylated anti-mouse IFN-γantibody (BD Pharmingen) was added (50 μl; 2.5 μg/ml in PBS–
0.05% Tween 20), and plates were incubated for 90 min at room
temperature. After extensive washes, streptavidin–alkaline phos-
phatase conjugate (Roche) was added (50 μl; 1 U/ml in PBS–0.05%
Tween 20) and plates were incubated 1 h at room temperature.
Spots were developed with BCIP/NBT (Promega) and counted in an
ELISpot Reader (Bio-Sys).
Activation of human HIV-speciﬁc T cells
Human dendritic cells and B-EBV cells (Moris et al., 2004; Moris
et al., 2006) were used to analyze the presentation of HIV-1 Gag
epitopes to HIV-1 Gag-speciﬁc CD8+ T cells and HIV-1 Gag-speciﬁc
CD4+ T cells, respectively. DCs and B-EBV were exposed to
recombinant MV–HIV viruses at different MOIs (0.5, 0.05, 0.01 for
DCs and 5, 1, 0.2 for B-EBV) in 0.5 ml RPMI for 2 h at 37 °C, 5% CO2.
Following infection cells were washed, resuspended at 1×106/ml
and incubated in 24-well plates (2 ml per well) at 37 °C, 5% CO2. After
24 h, a sample of each condition was removed for ELISPOT assay, and
the remainder returned to incubation for additional 24 h. Gag
expression in infected DCs or B cells was measured on permeabilized
cells using anti-Gagp24 mAb (KC57, FITC- or RD1-coupled, Coulter)
and analyzed by ﬂow cytometry (FACSCalibur and FlowJo software).
For IFN-γ ELISPOT assay, 96-well ELISPOT plates (MAHA S45,
Millipore) were coated overnight at 4 °C with mouse anti-human
IFN-γ antibody (Mabtech) at 10 μg/ml in 50 μl PBS. The plates were
washed with PBS and blocked with PBS–5% FCS for 1 h at room
temperature. Infected DCs or B-EBV cells were distributed in
triplicate at 1×105 cells per well. HIV-Gag speciﬁc CD8+ (clone
EM40) or CD4+ (clone F12) T cells were added at a ratio of 1:40 to
DCs and B-EBV, respectively. As a positive control, DCs and B-EBV
cells previously incubated with HIV-1 peptides (SL9 and gag2) were
also incubated with T cell clones at the same ratio. The plates were
incubated for 20 h at 37 °C, washed with PBS–0.05% Tween 20 and
incubated for 2 h with a biotin-conjugated anti-human IFN-γ
antibody (Mabtech). After washing, a streptavidin-horseradish
peroxidase complex (Roche) was added for 2 h incubation at room
temperature. The peroxidase activity was revealed with BCIP/NBT
(Promega France) and counted (ELISpot Reader; Bio-Sys).
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